Neuroinflammation is involved in the pathogenesis of Alzheimer’s disease, and the transcription factor NF-κB is a player in this event. We found here that the ischemic damage alone or in association with Aβ1-42 activates the NF-κB pathway, induces an increase of BACE1 and a parallel inhibition of Uch-L1 and TREM2, both in vitro and in vivo, in Tg 5XFAD and in human brains of sporadic AD. This mechanism creates a synergistic loop that fosters inflammation. We also demonstrated a significant protection exerted by the restoration of Uch-L1 activity. The rescue of the enzyme is able to abolish the decrease of TREM2 and the parameters of neuroinflammation.
SrinivasanM, LahiriDK (2015) Significance of NF-κB as a pivotal therapeutic target in the neurodegenerative pathologies of Alzheimer’s disease and multiple sclerosis. Expert Opin Ther Targets19, 471–487.
3.
ShiZM, HanYW, HanXH, ZhangK, ChangYN, HuZM, QiHX, TingC, ZhenZ, HongW (2016) Upstream regulators and downstream effectors of NF-κB in Alzheimer’s disease. Neurol Sci366, 127–134.
4.
Buggia-PrevotV, SevalleJ, RossnerS, CheclerF (2008) NFkappaB-dependent control of BACE1 promoter transactivation by Abeta42. J Biol Chem283, 10037–10047.
5.
ChenCH, ZhouW, LiuS, DengY, CaiF, ToneM, ToneY, TongY, SongW (2012) Increased NF-κB signalling up-regulates BACE1 expression and its therapeutic potential in Alzheimer’s disease. Int J Neuropsychopharmacol15, 77–90.
6.
GuglielmottoM, MonteleoneD, BoidoM, PirasA, GilibertoL, BorghiR, VercelliA, FornaroM, TabatonM, TamagnoE (2012) Aβ1-42-mediated down-regulation of Uch-L1 is dependent on NF-κB activation and impaired BACE1 lysosomal degradation. Aging Cell11, 834–844.
7.
GuglielmottoM, MonteleoneD, VasciaveoV, RepettoIE, ManasseroG, TabatonM, TamagnoE (2017) The decrease of Uch-L1 activity is a common mechanism responsible for Aβ 42 accumulation in Alzheimer’s and vascular disease. Front Aging Neurosci9, 320.
8.
ZhangH, SunY, HuR, LuoW, MaoX, ZhaoZ, ChenQ, ZhangZ (2013) The regulation of the UCH-L1 gene by transcription factor NF-κB in podocytes. Cell Signal25, 1574–1585.
9.
GongB,
LeznikE (2007) The role of ubiquitin C-terminal hydrolase L1 in neurodegenerative disorders. Drug News Perspect20, 365–370.
10.
LiuY, FallonL, LashuelHA, LiuZ, LansburyPTJr (2002) The UCH-L1 gene encodes two opposing enzymatic activities that affect alpha-synuclein degradation and Parkinson’s disease susceptibility. Cell111, 209–218.
11.
ZhengQ, HuangT, ZhangL, ZhouY, LuoH, XuH, WangX (2016) Dysregulation of ubiquitin-proteasome system in neurodegenerative diseases. Front Aging Neurosci8, 303.
12.
ChoiJ, LeveyAI, WeintraubST, ReesHD, GearingM, ChinLS, LiL (2004) Oxidative modifications and down-regulation of ubiquitin carboxyl-terminal hydrolase L1 associated with idiopathic Parkinson’s and Alzheimer’s diseases. J Biol Chem279, 13256–13264.
ZhongL, ZhangZL, LiX, LiaoC, MouP, WangT, WangZ, WangZ, WeiM, XuH, BuG, ChenXF (2017) TREM2/DAP12 complex regulates inflammatory responses in microglia via the JNK signaling pathway. Front Aging Neurosci9, 204.
17.
HanJ, WangM, RenM, LouH (2017) Contributions of triggering-receptor-expressed-on-myeloid-cells-2 to neurological diseases. Int J Neurosci127, 368–375.
18.
ChengJ, GuoX, ZhangT, ZhongL, BuG, ChenX (2016) TREMs in Alzheimer’s disease: Genetic and clinical investigations. Clin Chim Acta463, 88–95.
19.
DardiotisE, SiokasV, PantaziE, DardiotiM, RikosD, XiromerisiouG, MarkouA, PapadimitriouD, SpeletasM, HadjigeorgiouGM (2017) A novel mutation in TREM2 gene causing Nasu-Hakola disease and review of the literature. Neurobiol Aging53, 194.e13–194.e22.
20.
CarmonaS, ZahsK, WuE, DakinK, BrasJ,
GuerreiroR (2018) The role of TREM2 in Alzheimer’s disease and other neurodegenerative disorders. Lancet Neurol17, 721–730.
21.
BackhaussC, KarkoutlyC, WelschM, KrieglsteinJ (1992) A mouse model of focal cerebral ischemia for screening neuroprotective drug effects. J Pharmacol Toxicol Methods27, 27–32.
22.
DohareP, GargP, JainV, NathC, RayM (2008) Dose dependence and therapeutic window for the neuroprotective effects of curcumin in thromboembolic model of rat. Behav Brain Res193, 289–297.
23.
GongB, CaoZ, ZhengP, VitoloOV, LiuS, StaniszewskiA, MoolmanD, ZhangH, ShelanskiM, ArancioO (2006) Ubiquitin hydrolase Uch-L1 rescues beta-amyloid-induced decreases in synaptic function and contextual memory. Cell126, 775–788.
24.
ManasseroG, GuglielmottoM, ZamfirR, Borghi, ColomboL, SalmonaM, PerryG, OdettiP, ArancioO, TamagnoE, TabatonM (2016) Beta-amyloid 1-42 monomers, but not oligomers, produce PHF-like conformation of Tau protein. Aging Cell15, 914–923.
HolsingerRM, McLeanCA, BeyreutherK, MastersCL, EvinG (2002) Increased expression of the amyloid precursor beta-secretase in Alzheimer’s disease. Ann Neurol51, 783–786.
29.
BorghiR, PatriarcaS, TraversoN, PicciniA, StoraceD, GarutiA, CirmenaGabriella, OdettiPatrizio, TabatonMassimo (2007) The increased activity of BACE1 correlates with oxidative stress in Alzheimer’s disease. Neurobiol Aging28, 1009–1014.
30.
RansohoffRM (2016) How neuroinflammation contributes to neurodegeneration. Science353, 777–783.
31.
Villegas-LlerenaC, PhillipsA, Garcia-ReitboeckP, HardyJ, PocockJM (2016) Microglial genes regulating neuroinflammation in the progression of Alzheimer’s disease. Curr Opin Neurobiol36, 74–81.
32.
BennettML, BennettFC, LiddelowSA, AjamiB, ZamanianJL, FernhoffNB, MulinyaweSB, BohlenCJ, AdilA, TuckerA, WeissmanIL, ChangEF, LiG, GrantGA, Hayden GephartMG, BarresBA (2016) New tools for studying microglia in the mouse and human CNS. Proc Natl Acad Sci U S A113, E1738–E1746.
33.
SlevinM, LiuD, FerrisG, Al-HsinawiM, Al-BaradieR, KrupinskiJ (2017) Expression of monomeric C-reactive protein in infarcted brain tissue from patients with Alzheimer’s disease. Turk Patoloji Derg33, 25–29.
34.
RosciszewskiG, CadenaV, MurtaV, LukinJ, VillarrealA, RogerT, RamosAJ (2018) Toll-like receptor 4 (TLR4) and triggering receptor expressed on myeloid cells-2 (TREM-2) activation balance astrocyte polarization into a proinflammatory phenotype. Mol Neurobiol55, 3875–3888.
35.
FanY, MaY, HuangW, ChengX, GaoN, LiG, TianS (2019) Up-regulation of TREM2 accelerates the reduction of amyloid deposits and promotes neuronal regeneration in the hippocampus of amyloid beta1-42 injected mice. J Chem Neuroanat97, 71–79.
36.
Figueiredo-PereiraME, RockwellP, Schmidt-GlenewinkelT, SerranoP (2015) Neuroinflammation and J2 prostaglandins: Linking impairment of the ubiquitin-proteasome pathway and mitochondria to neurodegeneration. Front Mol Neurosci7, 104.
37.
WangZ, ArisVM, OgburnKD, SoteropoulosP, Figueiredo-PereiraME (2006) Prostaglandin J2 alters pro-survival and pro-death gene expression patterns and 26 S proteasome assembly in human neuroblastoma cells. J Biol Chem281, 21377–21386.
38.
IshiiT, SakuraiT, UsamiH, UchidaK (2005) Oxidative modification of proteasome: Identification of an oxidation-sensitive subunit in 26 S proteasome. Biochemistry44, 13893–13901.
39.
KoharudinLM, LiuH, Di MaioR, KodaliRB, GrahamSH, GronenbornAM (2010) Cyclopentenone prostaglandin-induced unfolding and aggregation of the Parkinson disease-associated UCH-L1. Proc Natl Acad Sci U S A107, 6835–6840.
